[Influence of fiberform on defecation condition after surgery for benign anorectal lesion].
OBJECTIVE
To explore the influence of fiberform on the defecation condition after surgery for benign anorectal lesion.


METHODS
A total of 121 cases undergoing surgery for benign anorectal lesion at the Third Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from October 2009 to February 2010 were randomly divided into the treatment group (n=61) and the control group (n=60) according to random number table. Patients in the treatment group received fiberform granule for 2 weeks while patients in the control group did not receive any medication to promote defecation. Postoperative defecation symptom scores and patient satisfaction were compared between the two groups.


RESULTS
On postoperative day 7, patients in the treatment group had a lower defecation smoothness score (62.1% decrease), lower fecal character score (74.3% decrease), lower defecation interval score (80.2% decrease), lower defecation pain score (77.5% decrease), the differences were statistically significant. On postoperative day 14, the degree of decrease of the abovementioned score were 58.3%, 88.5%, 82.8% and 83.1%, respectively. Postoperative patient satisfaction rate in the treatment group was significantly higher than that in the control group(P<0.05). No patient in the treatment group experienced any adverse events such as abdominal pain, diarrhea, and drug dependence.


CONCLUSIONS
Fiberform can effectively prevent defecation disorders such as dry stool, unsmooth defecation, and anorectal pain.
National Center of Colorectal Surgery, The Third Affiliated Hospital, Nanjing University of Traditional Chinese Medicine, Nanjing 210001, China.
Chao
C
Lei
Ye-huang
YH
Wang
Su-min
SM
Zhang
Ping
P
Jiang
Xue-xin
XX
Jiao
He-gen
HG
Huang
D015746:Abdominal Pain / Q000139:chemically induced; D001003:Anal Canal / Q000601:surgery*; D003672:Defecation / Q000187:drug effects*; D003967:Diarrhea / Q000139:chemically induced; D004043:Dietary Fiber / Q000008:administration & dosage*; D006801:Humans; D016896:Treatment Outcome